Literature DB >> 29582921

The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease.

Peter L Turecek, Michael Spannagl, Thorsten Kragh, Guenter Allmaier, Marietta Turecek, Gerald Schrenk, Herbert Gritsch, Ortrun Obermann-Slupetzky, Bruce M Ewenstein, Leonard A Valentino.   

Abstract

Ultralarge multimers (ULM) of VWF are considered to be the most active with respect to binding to platelets and to subendothelial structures and therefore are of critical importance for the function of VWF in stabilizing the primary hemostatic plug. In contrast to plasma-derived FVIII-VWF concentrates, human rVWF obtained from mammalian cell culture retains the full-spectrum of intact multimers, including ULM, as physiologically formed in the Golgi apparatus and stored in platelet α-granules and endothelial cell Weibel-Palade bodies. In the course of physico and biochemical, functional and animal studies, rVWF exhibited superiority in structure and function compared to pdVWF. These effects seemed to correlate with the multimer size and therefore might be attributed to the presence of ULM in rVWF preparations. The pharmacokinetic (PK), safety and efficacy characteristics seen in preclinical studies were further demonstrated in clinical trials. Schattauer GmbH.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29582921     DOI: 10.5482/HAMO-17-04-0018

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  2 in total

1.  Von Willebrand Factor Multimer Analysis by Low Resolution SDS-Agarose Gel Electrophoresis.

Authors:  Herbert Gritsch; Margit Stimpfl; Peter L Turecek
Journal:  Bio Protoc       Date:  2022-08-20

Review 2.  Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.

Authors:  Peter L Turecek; Jill M Johnsen; Steven W Pipe; James S O'Donnell
Journal:  Haemophilia       Date:  2020-06-28       Impact factor: 4.287

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.